🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. AT-1501

    Eledon Pharmaceuticals

    Kidney Transplant Rejection

    phase 2 small molecule active

    2 trials

  2. AT-1501

    Eledon Pharmaceuticals

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  3. AT-1501 IV Infusion

    Eledon Pharmaceuticals

    Brittle Type 1 Diabetes Mellitus

    phase 2 mab terminated

    1 trial

  4. AT-527

    Atea Pharmaceuticals

    COVID-19

    phase 2 small molecule terminated

    2 trials

  5. AT-527

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  6. AT-752

    Atea Pharmaceuticals

    Dengue Fever

    phase 2 small molecule terminated

    1 trial

  7. AT-777

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  8. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  9. AUY922

    Novartis Pharmaceuticals

    Advanced HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  10. AVN944

    Vertex Pharmaceuticals (Australia) Pty.

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  11. AXATILIMAB

    Syndax Pharmaceuticals

    Chronic graft versus host disease (cGVHD)

    phase 2 small molecule active

    1 trial

  12. AXATILIMAB, Placebo

    Syndax Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  13. Abemaciclib

    Teva Pharma GmbH

    Triple Negative Breast Neoplasms

    phase 2 small molecule active

    1 trial

  14. Abexinostat

    Xynomic Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  15. Abiprubart

    Kiniksa Pharmaceuticals International, plc

    Sjögrens Disease

    phase 2 small molecule terminated

    1 trial

  16. Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE

    Novartis Pharmaceuticals

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial

  17. Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial

  18. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  19. Active treatment with a high dose of BGS649

    Mereo BioPharma Group plc

    Endometriosis

    phase 2 small molecule completed

    1 trial

  20. Actrapid 100 international units/ml solution for injection in vial, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, SODIUM CHLORIDE, Natriumklorid Fresenius Kabi 9 mg/ml, spädningsvätska för parenteral användning, Albumin Baxalta 200 g/l infusionsvätska, lösning, Glucos Fresenius Kabi 200 mg/ml infusionsvätska, lösning, A24110He

    Lacuna Pharma Pty Ltd

    Moderate to severe hypertriglyceridemia

    phase 2 small molecule active

    1 trial

  21. Adtralza 150 mg solution for injection in pre-filled syringe

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 2 small molecule active

    1 trial

  22. Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release

    Astellas Pharma GmbH

    Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection

    phase 2 small molecule active

    1 trial

  23. Air médical en bouteille, OXYGEN

    Pari Pharma GmbH

    Alternating Hemiplegia of Childhood

    phase 2 small molecule active

    1 trial

  24. Albuterol DPI 25 mcg/inh

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources